US2014088162A1PendingUtilityA1

Treatment of Pulmonary Hypertension with Carbonic Anhydrase Inhibitors

59
Assignee: VIVUS INCPriority: Jun 13, 2007Filed: Sep 12, 2013Published: Mar 27, 2014
Est. expiryJun 13, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Thomas NajarianPeter Y. TamLeland F. WilsonCraig Peterson
A61P 9/12A61P 9/04A61K 31/522A61K 31/423A61K 31/198A61K 45/06A61K 31/444A61K 31/519A61K 31/433A61K 31/34A61K 31/7048A61K 31/4985A61K 31/415A61K 31/635A61K 31/18A61K 31/53A61P 11/16A61K 31/42A61K 31/506A61P 11/00A61K 31/357A61K 31/137A61K 31/382
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.

Claims

exact text as granted — not AI-modified
1 . A method for treating pulmonary hypertension in a patient, comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to the patient. 
     
     
         2 .- 65 . (canceled)

Join the waitlist — get patent alerts

Track US2014088162A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.